Andere Sprachen TransCode Therapeutics, Inc.

Aktien

A3E4PN

US89357L3033

RNAZ

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 28.06.2024			% 5 Tage	% 1. Jan.
1,005 ^USD	-0,50 %		+3,73 %	-84,75 %

29.05.	TransCode Therapeutics, Inc. meldet positive Daten aus der ersten klinischen Studie am Menschen mit dem neuartigen therapeutischen Leitkandidaten TTX-MC138	CI
15.05.	TransCode Therapeutics, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements	10.06.
TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138	29.05.
TransCode Therapeutics, Inc. Reports Positive Data from First-In-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138	29.05.
TransCode Therapeutics : Investor Presentation	23.05.
TransCode Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15.05.
TransCode Therapeutics Open Letter to Shareholders	13.05.
TransCode Therapeutics : Shareholder Meeting - Form 8-K	23.04.
Certain Warrants of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2024.	22.04.
Certain Stock Options of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2024.	22.04.
Certain Common Stock of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2024.	22.04.
TransCode Therapeutics Cleared by FDA for Phase 1/2 Trial of TTX-MC138 for Advanced Solid Tumors	15.04.
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors	15.04.
TransCode Therapeutics, Inc. Announces Fda Clearance to Initiate Phase 1/2 Clinical Trial Withttx-Mc138 in Patients with Advanced Solid Tumors	15.04.
TransCode Therapeutics Reports 2023 Results; Provides Business Update	03.04.
TransCode Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01.04.
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer	28.03.
TransCode Therapeutics, Inc. Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer	28.03.
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment	11.03.
TransCode Therapeutics, Inc. and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment	11.03.
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic	20.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen TransCode Therapeutics, Inc.

Aktien

A3E4PN

US89357L3033

RNAZ

Andere Sprachen

Filter